Molecular dissection of a hyper-aggressive CBFB-MYH11/FLT3-ITD–positive acute myeloid leukemia

Molecular dissection of a hyper-aggressive CBFB-MYH11/FLT3-ITD–positive acute myeloid leukemia

Acute Myeloid Leukaemia (AML) is a haematological malignancy showing a hypervariable landscape of clinical outcomes and phenotypic differences, explainable by heterogeneity at the cellular and molecular level. Among the most common genomic alterations, CBFB-MYH11 rearrangement and FLT3-ITD gene muta...

Full description

Bibliographic Details
Main Authors:	Ciliberto, G. (Author), De Bellis, E. (Author), De Nicola, F. (Author), Divona, M. (Author), Fanciulli, M. (Author), Goeman, F. (Author), Guarnera, L. (Author), Lo Iudice, G. (Author), Massacci, A. (Author), Ottone, T. (Author), Pallocca, M. (Author), Savi, A. (Author), Voso, M.T (Author)
Format:	Article
Language:	English
Published:	BioMed Central Ltd 2022
Online Access:	View Fulltext in Publisher

Similar Items

Primary peritoneal myeloid sarcoma in association with CBFB/MYH11 fusion
by: Justin J. Kuhlman, et al.
Published: (2021-01-01)

Hyper-methylation of the SOCS2 Promoter in AML: An Unexpected Association with the FLT3-ITD Mutation
by: McIntosh, Courtney
Published: (2009)

Hyper-methylation of the SOCS2 Promoter in AML: An Unexpected Association with the FLT3-ITD Mutation
by: McIntosh, Courtney
Published: (2009)

CBFB-MYH11 Fusion Sequesters RUNX1 in Cytoplasm to Prevent DNMT3A Recruitment to Target Genes in AML
by: Peng Liu, et al.
Published: (2021-07-01)

A novel cryptic CBFB-MYH11 gene fusion present at birth leading to acute myeloid leukemia and allowing molecular monitoring for minimal residual disease
by: P.J. Poddighe, et al.
Published: (2018-03-01)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
by: Chen, Y., et al.
Published: (2022)

Comparison of FLT3 inhibitors with the standard treatment for FLT3-ITD mutated acute myeloid leukemia
by: Argetsinger, Stephanie
Published: (2019)

The Role of the Juxtamembrane Domain of FLT3-ITDs in Acute Myeloid Leukemia
by: Vempati, Sridhar
Published: (2007)

Mechanism of sorafenib resistance in FLT3-ITD⁺ acute myeloid leukemia
by: Man, Cheuk-him, et al.
Published: (2014)

Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to Flt3-ITD mutations
by: Shaina N Porter, et al.
Published: (2016-11-01)

FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia
by: Mariko Takenokuchi, et al.
Published: (2012-10-01)

Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia
by: Katharina Sies, et al.
Published: (2019-04-01)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
by: Pankit Vachhani, et al.
Published: (2016-01-01)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
by: Silvia Waldeck, et al.
Published: (2020-04-01)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
by: Mark C Weir, et al.
Published: (2017-01-01)

De Novo Acute Myeloid Leukemia with Combined CBFB-MYH11 and BCR-ABL1 Gene Rearrangements: A Case Report and Review of Literature
by: Venkata Rakesh Sethapati, et al.
Published: (2020-01-01)

<i>FLT3</i>-ITD Allelic Burden and Acute Promyelocytic Leukemia Risk Stratification
by: Andrew Y. Li, et al.
Published: (2021-03-01)

FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation
by: Caroline Engen, et al.
Published: (2021-09-01)

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia
by: Shano Naseem, et al.
Published: (2021-01-01)

Effect of indirubin-3'-monoxime on FLT3-ITD acute myelogenous leukemia cell
by: 林志明

FLT3-ITD Mutation and FLT3 Ligand Plasma Level Were Not Associated with One-Year Survival of Indonesian Acute Myeloid Leukemia Patients
by: Rinaldi I, et al.
Published: (2021-02-01)

Sorafenib - induced thyroiditis in patient with a relapse of acute myelomonocytic leukemia with FLT3-ITD mutation
by: Ya B Balzhanova, et al.
Published: (2019-08-01)

How to Improve Prognostication in Acute Myeloid Leukemia with <i>CBFB-MYH11</i> Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring
by: Annalisa Talami, et al.
Published: (2021-08-01)

FLT3 and NPM1 gene mutations in patients with acute myeloid leukemias and the impact of FLT3-ITD mutations on the survival of patients with a normal karyotype
by: Irina Stepanovna Martynkevich, et al.
Published: (2010-12-01)

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
by: Bai‐Liang He, et al.
Published: (2020-04-01)

A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
by: Peihong Wang, et al.
Published: (2021-07-01)

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
by: Bai‐Liang He, et al.
Published: (2020-08-01)

FMS-LIKE TYROSINE KINASE (FLT3) GENE ITD MUTATION IN ACUTE MYELOID LEUKEMIA
by: Rajko Kusec, et al.
Published: (2004-12-01)

FLT3-ITDs Instruct a Myeloid Differentiation and Transformation Bias in Lymphomyeloid Multipotent Progenitors
by: Adam J. Mead, et al.
Published: (2013-06-01)

Effect of Sulfur Mustard Toxicity on FLT3-ITD Gene Mutation in Sulfur Mustard Veterans
by: Hossein Ayatollahi, et al.
Published: (2018-07-01)

CD52 is a novel target for the treatment of FLT3-ITD-mutated myeloid leukemia
by: Sivasundaram Karnan, et al.
Published: (2021-05-01)

Potential Effects of the FLT3-ITD Mutation on Chemotherapy Response and Prognosis of Acute Promyelocytic Leukemia
by: Song Y, et al.
Published: (2021-03-01)

FLT3-ITD Incidence and FLT-D835 Mutations in Acute Myeloid Leukemia Patients with Normal Karyotype in Morocco: A Preliminary Study
by: Hind Dehbi, et al.
Published: (2013-01-01)

Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling
by: Ying Xu, et al.
Published: (2021-01-01)

FLT3-ITD DNA allelic burden, but not mRNA levels, influences the biological characteristics of AML patients
by: Soare Dan S., et al.
Published: (2021-01-01)

Estudio del ratio de FLT3-ITD como factor pronóstico en leucemias agudas mieloides
by: Evangelina González, et al.
Published: (2016-09-01)

Maturation State-Specific Alternative Splicing in <i>FLT3</i>-ITD and NPM1 Mutated AML
by: Anna Wojtuszkiewicz, et al.
Published: (2021-08-01)

The Myc/Max/Mxd Network Is a Target of Mutated Flt3 Signaling in Hematopoietic Stem Cells in Flt3-ITD-Induced Myeloproliferative Disease
by: Farhan Basit, et al.
Published: (2018-01-01)

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation
by: Ruiqi Zhu, et al.
Published: (2021-05-01)

Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells
by: Jonathan Metts, et al.
Published: (2017-06-01)